CytomX Q3 revenue $33.4M (up 26% YoY); cash $117.6M; pipeline programs advance

CytomX Therapeutics, Inc.

Revenue $33.4M in Q3 2024, up from $26.4M in Q3 2023 (+26.5%).
Cash & investments $117.6M as of Sep 30, 2024 (down from $137.2M at June 30); runway to end of 2025.
CX-904 Phase 1a cleared 15 mg dose; Phase 1b possible in 2025 pending dose/schedule optimization.
CX-2051 Phase 1a in colorectal cancer in fifth dose cohort; initial data expected H1 2025.
CX-801 Phase 1a started, first patient dosed; initial data expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.